作者: Henryk Barthel , Osama Sabri , None
关键词:
摘要: PET imaging of amyloid-β has recently emerged as a valuable biomarker to support the in vivo diagnosis Alzheimer's disease (AD). So far, however, no tracer is available suitable for general clinical routine application. Florbetaben promising 18F-labeled amyloid-β-targeted currently Phase 2/3 development. This review provides an overview on current knowledge and future research activities florbetaben. Recently, first worldwide multi-center trial test diagnostic performance AD was conducted with this tracer. From trial, sensitivity specificity 80 91% discrimination between patients probable age-matched healthy controls reported. Ongoing florbetaben trials deal correlating signal post mortem histopathology evaluation, investigating value predict progression at stage mild cognitive impairment. The preclinical data verify safe efficacious detection deposition brain. results ongoing will contribute characteristics florbetaben, help determine potential visual adjunct supplement "AD toolbox".